The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Subscribe To Our Newsletter & Stay Updated
